What is the most recent earnings date for NAMS stock?
NEWAMSTERDAM PHARMA CO NV (NAMS) last reported earnings on 2/18/2026.
NEWAMSTERDAM PHARMA CO NV (NAMS) Earnings History & Surprises
NASDAQ:NAMS • NL00150012L7
Current stock price
30.06 USD
+0.05 (+0.17%)
At close:
30.06 USD
0 (0%)
After Hours:
NAMS Earnings overview
Past quarterly earnings results for NEWAMSTERDAM PHARMA CO NV (NAMS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.50
- Revenue Estimate
- 955.087K
Last Reported
Most Recent- Release Date
- Feb 18, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.62
- EPS Surprise
- -57.85%
- Revenue Surprise
- -99.39%
Beat Rate
Last 8 Quarters 0%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.62 | -0.39 | -57.85% | 33.33% | 32K | 5.222M | -99.39% | -99.75% |
| Q3 2025 | -0.61 | -0.40 | -50.97% | -238.89% | 348K | 5.392M | -93.55% | -98.80% |
| Q2 2025 | -0.15 | -0.50 | 70.09% | 63.41% | 19.145M | 1.63M | 1,074.54% | 740.06% |
| Q1 2025 | -0.34 | -0.50 | 31.66% | 67.92% | 2.978M | 1.607M | 85.31% | 112.56% |
| Q4 2024 | -0.93 | -0.50 | -87.61% | -60.07% | 12.772M | 1.791M | 613.12% | 1,521.66% |
| Q3 2024 | -0.18 | -0.51 | 64.67% | 67.54% | 29.111M | 1.91M | 1,424.14% | 877.73% |
| Q2 2024 | -0.41 | -0.59 | 30.32% | 11.09% | 2.279M | 1.406M | 62.09% | -76.17% |
| Q1 2024 | -1.06 | -0.54 | -97.14% | -142.72% | 1.401M | 1.778M | -21.20% | -49.86% |
| Q4 2023 | -0.58 | -0.61 | 4.67% | -18.67% | 787.59K | 1.998M | -60.58% | -99.19% |
| Q3 2023 | -0.55 | -0.50 | -11.52% | 9.31% | 2.977M | 2.291M | 29.96% | - |
| Q2 2023 | -0.46 | - | - | 9.562M | 2.794M | 242.23% | - | |
| Q1 2023 | -0.44 | - | - | 2.794M | - | - | ||
| Q4 2022 | -0.49 | - | - | 97.5M | 3.807M | 2,461.07% | - | |
| Q3 2022 | -0.61 | - | - | 1.785M | -100.00% | - | ||
| Q2 2022 | - | - | - | - | ||||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | - | - | - | - | ||||
| Q3 2021 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
N/A
Average EPS beat (4)
N/A
Max EPS beat (4)
N/A
Min EPS beat (4)
N/A
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
Related analysis
NEWAMSTERDAM PHARMA CO NV / NAMS Earnings FAQ
Did NAMS stock beat earnings estimates in the most recent quarter?
NEWAMSTERDAM PHARMA CO NV (NAMS) missed EPS estimates and missed revenue estimates in the most recent quarter.